Dermapharm Holding Se Stock Price To Sales
| DMP Stock | 37.80 0.10 0.26% |
Dermapharm Holding SE fundamentals help investors to digest information that contributes to Dermapharm Holding's financial success or failures. It also enables traders to predict the movement of Dermapharm Stock. The fundamental analysis module provides a way to measure Dermapharm Holding's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dermapharm Holding stock.
Dermapharm |
Dermapharm Holding SE Company Price To Sales Analysis
Dermapharm Holding's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Dermapharm Holding Price To Sales | 2.04 X |
Most of Dermapharm Holding's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dermapharm Holding SE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Dermapharm Holding SE has a Price To Sales of 2.043 times. This is 90.45% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers-Specialty & Generic industry. The price to sales for all Germany stocks is 82.11% higher than that of the company.
Dermapharm Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dermapharm Holding's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dermapharm Holding could also be used in its relative valuation, which is a method of valuing Dermapharm Holding by comparing valuation metrics of similar companies.Dermapharm Holding is rated below average in price to sales category among its peers.
Dermapharm Fundamentals
| Return On Equity | 0.38 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 2.68 B | |||
| Shares Outstanding | 53.84 M | |||
| Shares Owned By Insiders | 65.04 % | |||
| Shares Owned By Institutions | 17.12 % | |||
| Price To Book | 4.69 X | |||
| Price To Sales | 2.04 X | |||
| Revenue | 942.91 M | |||
| Gross Profit | 610.22 M | |||
| EBITDA | 357.65 M | |||
| Net Income | 209.58 M | |||
| Cash And Equivalents | 161.38 M | |||
| Total Debt | 574.72 M | |||
| Book Value Per Share | 9.36 X | |||
| Cash Flow From Operations | 250.37 M | |||
| Earnings Per Share | 3.32 X | |||
| Target Price | 56.3 | |||
| Number Of Employees | 2.37 K | |||
| Beta | 1.2 | |||
| Market Capitalization | 2.1 B | |||
| Total Asset | 1.41 B | |||
| Z Score | 1.8 | |||
| Annual Yield | 0.06 % | |||
| Net Asset | 1.41 B | |||
| Last Dividend Paid | 2.17 |
About Dermapharm Holding Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dermapharm Holding SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dermapharm Holding using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dermapharm Holding SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Dermapharm Stock Analysis
When running Dermapharm Holding's price analysis, check to measure Dermapharm Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermapharm Holding is operating at the current time. Most of Dermapharm Holding's value examination focuses on studying past and present price action to predict the probability of Dermapharm Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermapharm Holding's price. Additionally, you may evaluate how the addition of Dermapharm Holding to your portfolios can decrease your overall portfolio volatility.